TY - JOUR
AB - 
This Medical Letter review discusses the mechanism of action, adverse effects, and cost associated with coagulation factor Xa that was approved by the US Food and Drug Administration for reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban and rivaroxaban.

TI - Andexxa—An Antidote for Apixaban and Rivaroxaban
JF - JAMA
DO - 10.1001/jama.2018.9257
DA - 2018-07-24
UR - https://www.deepdyve.com/lp/american-medical-association/andexxa-an-antidote-for-apixaban-and-rivaroxaban-WxWmTSFbSA
SP - 399
EP - 400
VL - 320
IS - 4
DP - DeepDyve
ER -